IL-33 is known to attenuate IL-17 expression in EAE Experimental autoimmune encephalomyelitis and so D-gal–exposed osteoblasts were treated with IL-17 alone and with IL-33. Here, IL17A is linked to experimental autoimmune encephalomyelitis.